Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10221474 | 0.87 | SCN10A (0.36) | SCN10AKCNH2MEN1KMT2APDE10A | |
| SCHEMBL14329494 | 0.87 | KIF11 (0.41) | BACE1SCN10AMEN1KMT2A | |
| SCHEMBL14018671 | 0.84 | BACE1 (0.57) | BACE1PDE10ATERTMETAP2 | |
| SCHEMBL16492040 | 0.84 | BACE1 (0.38) | BACE1SCN10AKCNH2MEN1KMT2A | |
| SCHEMBL29485681 | 0.80 | MEN1 (0.38) | BACE1SCN10AKCNH2MEN1KMT2A | |
| SCHEMBL16492037 | 0.80 | MEN1 (0.38) | BACE1SCN10AKCNH2MEN1KMT2A | |
| SCHEMBL14157791 | 0.76 | PDE10A (0.50) | SCN10AKCNH2MEN1KMT2APDE10A | |
| SCHEMBL19170716 | 0.76 | SCN10A (0.37) | BACE1SCN10AKCNH2MEN1KMT2A | |
| SCHEMBL6230105 | 0.76 | CYP1A2 (0.59) | BACE1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL10182842 | 0.76 | CYP1A2 (0.59) | BACE1SCN10AKCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | BACE1 4020/4885SCN10A 3305/4885KCNH2 4528/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | BACE1 4020/4885SCN10A 3305/4885KCNH2 4528/4885 |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | BACE1 2803/4885SCN10A 3520/4885KCNH2 191/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | BACE1 2108/4885SCN10A 1246/4885KCNH2 296/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BACE1 3006/4885SCN10A 1960/4885KCNH2 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.